In conclusion, this retrospective study demonstrates that advanced NSCLC patients after EGFR-TKIs resistance may be able to achieve better clinical outcomes from the regimen of immunotherapy + antiangiogenic therapy + chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.